// App-Quantinova.ai

: Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program

Researchers

Presenter

  • Hector Ortega

Principal Investigators

  • Erik Meyer

  • Guy Brusselle

  • Koichiro Asano

  • Robert Price

  • Charlene Prazma

  • Frank Albers

  • Steven Yancey

  • Gerald Gleich

Medical Centers

  • UCSD, La Jolla, United States of America

  • Perelman School of Medicine, Philadelphia, United States of America

  • Respiratory Medicine, Leuven University Hospital, Leuven, Belgium

  • Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan,

  • GSK, Stevenage, Hertfordshire, United Kingdom

  • NIH/NIEHS, Research Triangle Park, United States of America

  • University of Utah, Utah, United States of America

Locations

  • United States

  • Belgium

  • Japan

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Mepolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Open Label

Phase

  • III

Study Id's

  • NCT01000506

  • NCT01691521

  • NCT01691508

  • NCT01842607

  • NCT01691859

Sponsors

  • Glaxosmithkline

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved